Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Aethlon Medical begins clinical testing of Hemopurifier

Aethlon Medical : 28 June, 2007  (New Product)
Aethlon Medical is to start clinical testing of the Hemopurifier in human studies to be conducted at the Fortis Hospital in Delhi, India.
The study, approved by the Ethics Committee for Research at Fortis Hospital, will evaluate safety of the Hemopurifier in up to ten patients with end-stage renal disease.

Pending patient accrual, the study is expected to begin in August 2007.
Dr Vijay Kher, director of nephrology at Fortis has agreed to be the principal investigator of the study.

Previously, Dr Kher acted as principal investigator of a Hemopurifier study conducted at the Apollo Hospital in Delhi.

The Apollo study documented initial safety of the Hemopurifier, and provided early efficacy observations during 24-treatments administered to health compromised dialysis patients co-infected with Hepatitis-C (HCV).

The Fortis study supports Aethlon's strategy to pursue early treatment and commercialisation opportunities in India.

Aethlon will focus on viral conditions of greatest concern to Indian citizens, and opportunities that offer treatment access to the Hemopurifier within India's growing medical tourism industry.

Targeted conditions may include Dengue Haemorrhagic Fever (DHF), HIV/AIDS, and HCV.

At present, regulatory barriers specific to the Hemopurifier do not exist in India.

As a result, introduction of the Hemopurifier into the marketplace will be based on obtaining sufficient clinical data to drive practitioner acceptance in the marketplace.

As with previous pre-clinical and clinical programs in India, Aethlon will seek additional support and guidance from the Indian Council of Medical Research (ICMR).

Aethlon may also consult with the Food and Drug Administration (FDA) on protocol design and will provide the FDA with clinical data obtained from studies as a means to potentially augment clinical efforts to advance the Hemopurifier as a broad spectrum countermeasure against bioterror threats in the USA.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo